当前位置: X-MOL 学术Clin. Chim. Acta › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RASSF1A: A promising target for the diagnosis and treatment of cancer.
Clinica Chimica Acta ( IF 3.2 ) Pub Date : 2020-01-23 , DOI: 10.1016/j.cca.2020.01.014
Yuling Bin 1 , Yong Ding 2 , Weisheng Xiao 1 , Aijun Liao 1
Affiliation  

The Ras association domain family 1 isoform A (RASSF1A), a tumor suppressor, regulates several tumor-related signaling pathways and interferes with diverse cellular processes. RASSF1A is frequently demonstrated to be inactivated by hypermethylation in numerous types of solid cancers. It is also associated with lymph node metastasis, vascular invasion, and chemo-resistance. Therefore, reactivation of RASSF1A may be a viable strategy to block tumor progress and reverse drug resistance. In this review, we have summarized the clinical value of RASSF1A for screening, staging, and therapeutic management of human malignancies. We also highlighted the potential mechanism of RASSF1A in chemo-resistance, which may help identify novel drugs in the future.

中文翻译:

RASSF1A:用于癌症诊断和治疗的有希望的靶标。

Ras关联域家族1亚型A(RASSF1A),一种肿瘤抑制因子,调节几种与肿瘤相关的信号传导途径,并干扰多种细胞过程。RASSF1A经常被证明在许多类型的实体癌中会因甲基化而失活。它也与淋巴结转移,血管浸润和抗化学性有关。因此,RASSF1A的重新激活可能是阻止肿瘤进展和逆转耐药性的可行策略。在这篇综述中,我们总结了RASSF1A在筛查,分期和治疗人类恶性肿瘤方面的临床价值。我们还强调了RASSF1A在抗化学性中的潜在机制,这可能有助于将来鉴定新药。
更新日期:2020-01-23
down
wechat
bug